RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS INFECTIONS trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New mRNA RSV vaccine enters first human tests
⭐️ VACCINE ⭐️ OngoingThis early-stage study tests an experimental mRNA vaccine designed to protect against respiratory syncytial virus (RSV). Around 213 healthy adults aged 18-45 will receive different doses to check safety and immune response. The goal is to find a well-tolerated dose for future lar…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 13:54 UTC
-
New RSV vaccine shows promise for seniors
⭐️ VACCINE ⭐️ OngoingThis study tests an experimental RSV vaccine in adults aged 60 and older. The goal is to see how well the vaccine triggers the immune system, how safe it is, and how long protection lasts—up to 5 years. About 1,720 participants will receive one or more doses to find the best vacc…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated May 15, 2026 11:57 UTC
-
RSV vaccine booster study aims to protect seniors for five seasons
⭐️ VACCINE ⭐️ OngoingThis study looks at the best time to give a second dose of the RSV vaccine to adults aged 60 and older. It also checks how long protection from a single dose lasts over up to five RSV seasons. About 10,000 participants from a previous study will take part, and those who received …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated May 15, 2026 11:53 UTC
-
New mRNA vaccine aims to shield adults from RSV
⭐️ VACCINE ⭐️ OngoingThis early-stage study tests a new mRNA vaccine (IN006) designed to protect against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. About 240 healthy adults aged 18 and older will receive either the vaccine or a placebo to check for side …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE1 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated May 13, 2026 16:02 UTC
-
New RSV vaccine trial aims to protect vulnerable transplant patients
Disease control OngoingThis study tests a non-live RSV vaccine in 100 adults who have received a lung or stem cell transplant. The goal is to see if the vaccine is safe and helps their immune system fight RSV, a common virus that can be dangerous for them. Participants will give blood samples and be mo…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE3 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 08, 2026 12:04 UTC